CN105368806A - 一种定点突变改造的酵母二肽基肽酶iii - Google Patents
一种定点突变改造的酵母二肽基肽酶iii Download PDFInfo
- Publication number
- CN105368806A CN105368806A CN201510908511.8A CN201510908511A CN105368806A CN 105368806 A CN105368806 A CN 105368806A CN 201510908511 A CN201510908511 A CN 201510908511A CN 105368806 A CN105368806 A CN 105368806A
- Authority
- CN
- China
- Prior art keywords
- dipeptidyl peptidase
- yeast
- site
- yeast dipeptidyl
- mutation modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 39
- 102100020750 Dipeptidyl peptidase 3 Human genes 0.000 title abstract description 28
- 101000931862 Homo sapiens Dipeptidyl peptidase 3 Proteins 0.000 title abstract description 28
- 238000002741 site-directed mutagenesis Methods 0.000 title abstract description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 title description 25
- 102000004190 Enzymes Human genes 0.000 claims abstract description 21
- 108090000790 Enzymes Proteins 0.000 claims abstract description 21
- 230000035772 mutation Effects 0.000 claims abstract description 20
- 239000000654 additive Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 15
- 239000004472 Lysine Substances 0.000 claims description 10
- 235000004279 alanine Nutrition 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
- 150000001413 amino acids Chemical group 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 claims 10
- 108090000212 dipeptidyl peptidase II Proteins 0.000 claims 10
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims 9
- 229960000956 coumarin Drugs 0.000 claims 3
- 235000001671 coumarin Nutrition 0.000 claims 3
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 14
- 238000006467 substitution reaction Methods 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 4
- 241000235070 Saccharomyces Species 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 229930195730 Aflatoxin Natural products 0.000 description 8
- 239000005409 aflatoxin Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 102000004860 Dipeptidases Human genes 0.000 description 5
- 108090001081 Dipeptidases Proteins 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 210000001938 protoplast Anatomy 0.000 description 5
- 241000235058 Komagataella pastoris Species 0.000 description 4
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 4
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000006864 oxidative decomposition reaction Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241001506991 Komagataella phaffii GS115 Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108010082737 zymolyase Proteins 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000348 Angiotensin-3 Human genes 0.000 description 1
- 101800000738 Angiotensin-3 Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 244000253724 Saccharomyces cerevisiae S288c Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- -1 alanine amino acid Chemical class 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000006400 oxidative hydrolysis reaction Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
- C12N1/185—Saccharomyces isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/85—Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14004—Dipeptidyl-peptidase III (3.4.14.4)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明涉及一种定点突变改造的酵母二肽基肽酶III。本发明所述的定点突变改造的酵母二肽基肽酶III,其特征在于:它是由氨基酸序列为SEQ?ID?NO.1的来源于Saccharomyces?cerevisiae?S288c的酵母二肽基肽酶III中制造多个氨基酸取代而产生的突变体,所述的氨基酸取代包括第570、572、574位的取代,以致所述定点突变改造的酵母二肽基肽酶III为对6-甲氧基双呋喃香豆素具有氧化分解作用的酶。本发明所述的定点突变改造的酵母二肽基肽酶III可应用于制备饲料及其添加剂或食品及其添加剂中消除6-甲氧基双呋喃香豆素的产品,还可应用于制备预防由6-甲氧基双呋喃香豆素诱发的疾病的药物。
Description
技术领域
本发明涉及一种二肽基肽酶III,特别涉及一种定点突变改造的酵母来源的二肽基肽酶III。
背景技术
二肽酶III(DPPSIII,EC3.4.14.4),如来自酵母的二肽酶III、来自人类的二肽酶III、来自大鼠的二肽酶III、来自兔的二肽酶III等,是一组分子内含有特殊的HEXXGH锌指结构的金属蛋白酶,具有水解多肽链的氨基末端切掉二肽的肽酶。DPPIII在生理功能上与脑啡肽和血管紧张素II、血管紧张素III、促黑色素等重要的生理活性肽的新陈代谢有关。DPPS存在于各种哺乳动物的组织中,根据亚细胞的定位、特异性地无核抑制剂的敏感性,二肽基肽酶分成不同的类型DPPI~DPPIV。DPPIII可以选择性地从多肽链或蛋白质的N-末端水解掉二肽残基,如:Arg-Arg-,Ala-Arg-,或者Tyr-Gry。酵母来源的DPPIII由712个氨基酸组成,锌离子是其催化金属离子。其氨基酸序列与黄曲霉毒素单加氧酶(Aflatoxinmonooxygenas,AFMO)的同源性达到37%,但不具有对6-甲氧基双呋喃香豆素氧化分解的功能。
黄曲霉毒素主要是由黄曲霉和寄生曲霉等真菌产生的剧毒性次生代谢产物,已经确定的黄曲霉毒素分子的结构主要有八种,其中毒性最强的黄曲霉毒素B1(也称6-甲氧基双呋喃香豆素)被认为是潜在的对人类危害极为突出的一类强致癌诱变剂,一次大量摄入会引起人及动物的急性中毒、甚至死亡;小剂量长期摄入会致畸、致突变和致癌,即使几十ppb的含量仍有极大的毒性;I族黄曲霉毒素含有呋喃双键结构。目前,已经发现的对6-甲氧基双呋喃香豆素具有分解作用的生物酶极少。黄曲霉毒素单加氧酶(AFMO)是一个对6-甲氧基双呋喃香豆素有氧化分解作用的酶。经研究发现黄曲霉毒素单加氧酶氧化分解6-甲氧基双呋喃香豆素的过程为:从底物分子中获得电子传递给氧,使水还原成过氧化氢,将底物氧化并进一步使分子中的呋喃双键开环。在这个过程中,由分子内的变价离子的价态变化来实现电子的传递,首先,结合在AFMO上的二价金属离子夺得底物的一个电子,自身变成一价离子,然后不稳定的一价离子将夺得的这个电子传递给氧,自身又转变成稳定的二价离子,氧气分子获得一个电子在水分子的参与下生成过氧化氢,同时底物转变为它的环氧化物。然后,该环氧化物伴随着过氧化氢的作用发生氧化水解反应,最终使底物分子中的呋喃双键断开。黄曲霉毒素单加氧酶是目前已报道的用于黄曲霉毒素解毒的生物酶。因此,发现和制造新的对6-甲氧基双呋喃香豆素具有氧化分解作用的酶,对发展黄曲霉毒素消减技术具有十分重要的现实意义。
发明内容
本发明的首要目的是提供一种定点突变的酵母二肽基肽酶III,该酵母二肽基肽酶III突变体对6-甲氧基双呋喃香豆素具有氧化分解功能。
本发明所述的一种定点突变改造的酵母二肽基肽酶III是由氨基酸序列为SEQIDNO.1的来源于酵母SaccharomycescerevisiaeS288c的酵母二肽基肽酶III(NCBI数据库登录号为NM_001183312)中制造多个氨基酸取代而产生的、对6-甲氧基双呋喃香豆素有氧化分解作用的酵母二肽基肽酶III突变体,所述的氨基酸取代包括第570、572和574位的取代。
根据本发明所述的定点突变改造的酵母二肽基肽酶III的进一步特征,所述第570位的氨基酸用丙氨酸(Alanine,ALa,A)取代赖氨酸(Lysine,Lys,K);第572位的氨基酸取代是用赖氨酸(Lysine,Lys,K)取代甘氨酸(Glycine,Gly,G);第574位的氨基酸取代是用组氨酸(Histidine,His,H)取代色氨酸(Tryptophan,Trp,W);所述的定点突变改造的酵母二肽基肽酶III突变体的氨基酸序列为SEQIDNO.2。
经实验验证,本发明所述的定点突变改造的酵母二肽基肽酶III(以下缩写为“myDPP”)具有对于6-甲氧基双呋喃香豆素的氧化分解功能。该突变体酶在pH6.0、反应温度25℃处理6-甲氧基双呋喃香豆素(100ppb)50分钟后,其对6-甲氧基双呋喃香豆素的氧化分解效率达到90%。该突变体酶的其它酶学性质与野生酶相似。
进一步地,本发明提供了一种DNA分子,其编码本发明所述的定点突变改造的酵母二肽基肽酶III。
优选地,本发明所述的DNA分子的核苷酸序列为SEQIDNO.3。
本发明的另一个目的是提供一种载体,其含有本发明所述的DNA分子。
本发明的又一个目的是提供一种宿主细胞,其含有本发明所述的DNA分子,或者含有本发明所述的载体。
上述载体和宿主细胞都可以通过本领域公知的技术手段进行制备。
本发明还提供了本发明所述的定点突变改造的酵母二肽基肽酶III的生产方法,包括:在适于二肽基肽酶III表达的条件下培养本发明所述的宿主细胞,并从培养基中分离所述的酵母二肽基肽酶III。
当本发明所述的DNA分子以合适的取向和正确的阅读框插入到所述的载体或者转入所述的宿主细胞中,所述的DNA分子可以在任何真核或者原核表达系统中表达。许多宿主-载体系统都可以用来表达蛋白质编码序列。宿主-载体系统包括但不限于:用噬菌体、质粒或粘粒转化的细菌;含有酵母载体的微生物,如酵母;用病毒感染的哺乳动物细胞系统;用病毒感染的昆虫细胞系统;用细菌感染的植物细胞系统。本发明优选的载体包括病毒载体、质粒、粘粒或者寡核苷酸。
本发明优选的宿主为真核系统如毕赤酵母;本发明优选的蛋白质表达方法为毕赤酵母甲醇诱导分泌表达。
本发明人成功地获得了一种定点突变改造的酵母二肽基肽酶III,通过活性鉴定实验,证明该二肽基肽酶III突变体具有野生型二肽基肽酶III所不具备的氧化分解6-甲氧基双呋喃香豆素的生物活性,且该生物活性达到了应用于饲料及其添加剂加工、食品及其添加剂加工以及药物开发的程度。
本发明的另一目的是提供将所述的定点突变改造的酵母二肽基肽酶III在制备饲料及其添加剂或食品及其添加剂中消除6-甲氧基双呋喃香豆素的产品的应用。结合目前的饲料和食品的加工工艺,可将本发明所述的定点突变改造的酵母二肽基肽酶III作为脱毒剂添加到饲料中进行饲料脱毒,或者制成固定化酶用于如花生油等食品的脱毒,或制成能够表达该酶的益生菌制剂或益生菌微囊等用于食品、粮油、饲料等的脱毒。
本发明的另一目的是提供将所述的定点突变改造的酵母二肽基肽酶III在制备预防由6-甲氧基双呋喃香豆素诱发的疾病的药物的应用。结合目前的常规药物制备工艺,可用本发明所述的定点突变改造的酵母二肽基肽酶III制得到用于预防由6-甲氧基双呋喃香豆素诱发的疾病(例如肿瘤)的药物。
附图说明
图1为重组质粒myDPP表达质粒的鉴定图。
图2为重组myDPP和重组wtyDPP的纯化结果。
具体实施方式
本文中所采用的术语,除非另有说明,均为本领域技术人员所通常理解的含义。以下提供在本发明中使用的一些特殊术语的定义。
“wtyDPP”表示野生型酵母二肽基肽酶III,其基因以斜体wtyDPP表示。
“myDPP”表示突变体酵母二肽基肽酶III,其基因以斜体myDPP表示。
实施例1:wtyDPP和myDPP的合成
本发明以SaccharomycescerevisiaeS288c的二肽基肽酶基因(NCBI数据库NM_001183312)序列作为参考,在5’端加入5’-GTCGAATTC-3’在3’端加入3’-CCTAGGGAC-5’,(GAATTC)为限制酶切位点EcoRI,(GGATCC)为限制酶切位点BamHI。采用人工全合成的方法合成wtyDPP基因。
本发明以SaccharomycescerevisiaeS288c的二肽基肽酶基因(NM_001183312)序列作为参考,将第570位的氨基酸用丙氨酸(Alanine,ALa,A)取代,第572位的氨基酸用赖氨酸(Lysine,Lys,K)取代,第574位的氨基酸用组氨酸(Histidine,His,H)取代,在5’端加入5’-GTCGAATTC-3’在3’端加入3’-CCTAGGGAC-5’,(GAATTC)为限制酶切位点EcoRI,(GGATCC)为限制酶切位点BamHI。采用人工全合成的方法合成myDPP目的基因。
在定点突变改造后,第570位的丙氨酸(Alanine,ALa,A)、第572位的赖氨酸(Lysine,Lys,K)、第574位的组氨酸(Histidine,His,H)与第576位的谷氨酰胺(Glutamine,Gln,Q)、第578位的组氨酸(Histidine,His,H)、第579位的甲硫氨酸(Methionine,Met,M)、第580位的谷氨酰胺(Glutamine,Gln,Q)、第581位的丙氨酸(Alanine,ALa,A)以及第582位的精氨酸(Arginine,Arg,R)形成一个AXKXHXQXHMQAR(其中,A为丙氨酸,R为精氨酸,X为任意氨基酸)序列。
基因合成由商业性公司(例如上海捷瑞生物有限公司)完成。
实施例2:重组质粒wtyDPP和myDPP表达质粒的构建
基因克隆按常规方法(Sambrook,etal.2001,MolecularCloningALaboratoryManual.ColdSpringHarborLabroratoryPress.USA)进行,将实施例1所得的wtyDPP和myDPP分别克隆到pHIL-S1构建成表达质粒pHIL-S1-wtyDPP和表达质粒pHIL-S1-myDPP,克隆后的目的基因经酶切、测序鉴定。
具体做法:
含myDPP的重组质粒pHIL-S1的构建过程为:EcoRI+BamHI双酶切质粒pHIL-S1和目的片断myDPP,酶切产物进行0.8%琼脂糖凝胶电泳,并切胶回收。利用T4DNA连接酶进行质粒pHIL-S1和myDPP的连接。CaCl2法制备E.coliDH5α感受态细胞,转化DH5α感受态细胞,筛选转化子,碱提质粒。用EcoRI+BamHI、HindⅢ、SacI酶切鉴定重组质粒pHIL-S1-myDPP。挑取重组质粒PEG纯化法(Sambrook,etal.2001,MolecularCloningALaboratoryManual.ColdSpringHarborLabroratoryPress.USA)提取质粒DNA。以T7和SP6为测序引物,采用DNA自动序列仪,正反向进行测定。酶切结果如图1示,重组载体pHIL-S1-myDPP的酶切鉴定,BamHI、EcoRI双酶切(样品1)切下一条带位于2100bp左右,HindIII单酶切(样品2),SacI单酶切(样品3)。
含wtyDPP的重组质粒pHIL-S1的构建过程为:将含myDPP的重组质粒pHIL-S1的构建过程中的目的片断myDPP替换为wtyDPP,其他操作过程与含myDPP的重组质粒pHIL-S1的构建过程相同。
实施例3:重组myDPP和重组wtyDPP的表达
重组myDPP的表达:用SacI酶切重组质粒pHIL-S1-myDPP和质粒pHIL-S1,酶切产物进行0.8%琼脂糖凝胶电泳,切胶回收酶切后的线性重组质粒pHIL-S1-myDPP和质粒pHIL-S1。按PichiaExpressionKit(InvitrogenInc.,美国)手册中的原生质法转化毕赤酵母菌GS115,筛选Mut+转化子。利用甲醇作为唯一碳源对重组菌进行诱导表达(按PichiaExpressionKit手册操作)中,培养液经SDS-PAGE电泳分析表明,转化子经诱导表达后,培养液上清出现明显的目的蛋白带,而转化不含目的基因的空质粒的对照菌在相同的条件下诱导96小时,在上清中未检测到目的蛋白条带。结果如图2所示(样品1为myDPP,样品2为wtyDPP),转化子经甲醇诱导表达后,培养液上清出现明显的目的蛋白带;而转化不含目的基因的空质粒的阴性对照菌,在相同的条件下诱导在上清中无目的蛋白出现。
具体做法如下:
一、重组子与毕赤酵母的同源重组
(一)线性化质粒
SacI酶切重组质粒pHIL-S1-myDPP和质粒pHIL-S1,同时线性化质粒pHIL-S1是作为下面实验的对照。
酶切pHIL-S1-myDPP(120总体系):12μlBufferL+8μlSacI+100μlpHIL-S1-myDPP
酶切pHIL-S1(120总体系):12μlBufferL+8μlSacI+100μlpHIL-S1
0.8%琼脂糖凝胶电泳酶切样品,切胶回收酶切后的线性重组质粒pHIL-S1-myDPP和质粒pHIL-S1。
(二)培养用于原生质化的毕赤酵母菌GS115
1.从平板上挑取一个GS115单克隆接种于10mlYPD中,在150ml锥形瓶中,30℃,250-300rpm振荡培养过夜;
2.从昨日培养的的10mlYPD菌液中分别取5,10,20μl接种于200mlYPD中,在500ml的锥形瓶中,250-300rpm振荡培养过夜;
3.检测3个瓶中菌液的OD600值,取OD600=0.2-0.3的菌液转入离心管中,室温1500×g离心5min,弃上清,收集的细胞用于原生质化。
(三)毕赤酵母菌GS115的原生质化
1.培养收集的细胞重悬于200ml的无菌水中,转移至两个无菌的10ml离心管中;
2.室温下,1500×g离心5min,弃上清;
3.用10ml新鲜配制的SED洗沉淀,室温下,1500×g离心5min,弃上清;
4.用10ml1M山梨醇洗沉淀,室温下,1500×g离心5min,弃上清;
5.用10mlSCE重悬沉淀;
6.取一管Zymolyase冻融后轻弹管壁,使溶液混匀;
7.取7.5μlZymolyase加入管中,30℃温育30min;
8.室温下750×g离心10min,收集菌体,弃上清;
9.用10ml1M山梨醇洗原生质体,轻轻敲打管壁分散沉淀,室温下750×g离心10min,收集菌体,弃上清;
10.用10mlCaS洗菌体,室温下750×g离心10min,收集菌体,弃上清;
11.将沉淀重悬于0.6mlCaS中,此原生质体在30min内必须使用。
(四)原生质法转化毕赤酵母菌GS115
1、分别取100μl毕赤酵母原生质体加入A、B、C3个无菌15ml离心管中;
2、A管中不加DNA作为阴性对照,B管中加入30μl线性化的原质粒pHIL-S1,C管中加入30μl线性化的重组质粒pHIL-S1-myDPP,室温下温育10min,期间准备一支3ml新鲜配制的PEG/CaT;
3、各管中加入1ml新鲜配制的PEG/CaT,轻轻混匀,室温下温育10min;
4、室温下750×g离心10分钟,弃上清,控干;
5、将沉淀重悬于150μlSOS中,室温温育20min;
6、各管加入850μl1M山梨醇,准备铺板;
7、涂布RD固体培养基,每板涂布200μl,28-30℃温育倒置培养,转化子约在4-6天出现。
(五)筛选Mut+转化子
1.用无菌牙签挑取His+转化子,分别在MM和MD板上一一对应点菌,同时点上GS115/His+MutsAlbumin和GS115/His+Mut+β-gal作为对照。
2.28-30℃温育倒置培养2天;
3.两天后,观察对照MM和MD板,若在两板上均生长良好为Mut+,若在MD上生长良好,在MM板上生长少或不生长则为Muts。
(六)重组菌的诱导表达
1.挑取一个His+Mut+转化子的单克隆,接种于25mlBMG,在250ml的锥形瓶中,28-30℃,250-300rpm振荡培养,直至OD600=2-6(约16-18h);
2.1500-3000×g离心5min收集细胞,弃上清,重悬细胞于BMM中至OD600为1.0(约需100-200mlBMM),在1升的锥形瓶中,28-30℃,250-300rpm继续振荡培养。
3.每24h加100%甲醇,始终浓度至0.5%,保持诱导表达;
4.诱导表达96h的时间。培养液离心2-3min,留取上清放入-80℃保存以用于纯化表达产物。
经诱导96小时培养上清中总蛋白量达0.23mg/ml。目的蛋白的分子量与理论值78kDa相符。
重组wtyDPP的表达:将重组myDPP的表达过程中的重组质粒替换为pHIL-S1-wtyDPP,其他操作过程与重组myDPP的表达流程相同。
实施例4:重组myDPP和wtyDPP的纯化
诱导表达的发酵液经70%饱和(NH4)2SO4沉淀,收取沉淀获得粗酶样品。粗酶样品以等体积的PBS溶解,离心后取上清上疏水色谱层析Phenylsepharose柱,以连续梯度的洗脱缓冲液洗脱,收集目的峰。透析脱盐,PBS溶液平衡后浓缩。具体如下:
1、硫酸氨沉淀收集粗酶
重组表达发酵液加入(NH4)2SO4粉末至40%饱和度,4℃,10000g离心20分钟,上清继续再加入(NH4)2SO4粉末至70%饱和度。4℃,10000g离心20分钟。即获得粗酶样品。
2、疏水层析:粗酶样品以等体积的0.02MPBS(pH:6.0)液溶解,4000g4℃离心10分钟,取上清,上Phenylsepharose柱[Phenylsepharose6Fastflow(highsub),PharmaciaBiotech,Inc],溶液液(0.02MPBS+30%饱和硫酸铵,pH:6.0)洗至基线,然后以连续梯度的洗脱缓冲液[A液(0.02MPBS+10%饱和硫酸铵,pH:6.0)+B液(0.02MPBS,pH:6.0)]洗脱,收集目的峰。透析脱盐,并以F液(0.02MPBS+0.5MNaCl,pH:7.5)平衡,浓缩至蛋白浓度约为1mg/ml。目的峰用SDS-PAGE电泳鉴定。
实施例5:myDPP及wtyDPP重组蛋白的对6-甲氧基双呋喃香豆素氧化分解作用的检测
酶活力单位的定义:25℃条件下,一分钟酶催化底物产生1μmol的H2O2所需要的酶量。
酶活力测定方法:
在10ml浓度为10μg/ml的酶中加入30μl浓度为100μg/ml的底物(6-甲氧基双呋喃香豆素),在25℃、pH6.5条件下反应10分钟,然后在反应液中加入200μl浓度为0.34mg/ml的辣根过氧化物酶(HRP)和200μl浓度为5mM的3,3’-5,5’-四甲基联苯胺(TMB),显色30min,然后在紫外650nm处测量吸光值,计算酶活力单位。
酶活测定结果显示,wtyDPP蛋白对6-甲氧基双呋喃香豆素没有分解作用;myDPP蛋白对6-甲氧基双呋喃香豆素具有分解作用,相对酶活为33.61U/mg。
表1:样品处理方法
Claims (9)
1.一种定点突变改造的酵母二肽基肽酶III,其特征在于:它是由氨基酸序列为SEQIDNO.1的来源于SaccharomycescerevisiaeS288c的酵母二肽基肽酶III中制造多个氨基酸取代而产生的突变体,所述的氨基酸取代包括第570、572、574位的取代,以致所述定点突变改造的酵母二肽基肽酶III为对6-甲氧基双呋喃香豆素具有氧化分解作用的酶。
2.根据权利要求1所述的定点突变改造的酵母二肽基肽酶III,其特征在于:所述第570位的氨基酸取代是用丙氨酸(Alanine,ALa,A)取代赖氨酸(Lysine,Lys,K);第572位的氨基酸取代是用赖氨酸(Lysine,Lys,K)取代甘氨酸(Glycine,Gly,G);第574位的氨基酸取代是用组氨酸(Histidine,His,H)取代色氨酸(Tryptophan,Trp,W);所述的定点突变改造的二肽基肽酶的氨基酸序列为SEQIDNO.2。
3.一种DNA分子,其特征在于:其编码权利要求2所述的定点突变改造的酵母二肽基肽酶III。
4.根据权利要求3所述的DNA分子,其特征在于:其核苷酸序列为SEQIDNO.3。
5.一种载体,其特征在于:其含有权利要求3或4所述的DNA分子。
6.一种宿主细胞,其特征在于:其含有权利要求3或4所述的DNA分子,或者含有权利要求5所述的载体。
7.一种根据权利要求1所述的定点突变改造的酵母二肽基肽酶III的生产方法,其特征在于,所述方法包括:在适于二肽基肽酶III表达的条件下培养权利要求6所述的宿主细胞,并从培养基中分离所述的酵母二肽基肽酶III。
8.如权利要求1所述的定点突变改造的酵母二肽基肽酶III在制备饲料及其添加剂或食品及其添加剂中消除6-甲氧基双呋喃香豆素的产品的应用。
9.如权利要求1所述的定点突变改造的酵母二肽基肽酶III在制备预防由6-甲氧基双呋喃香豆素诱发的疾病的药物的应用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510908511.8A CN105368806B (zh) | 2015-12-09 | 2015-12-09 | 一种定点突变改造的酵母二肽基肽酶iii |
US15/780,903 US20190246664A1 (en) | 2015-12-09 | 2016-11-28 | Site-specific mutagenesis modified yeast dipeptidyl peptidase iii |
PCT/CN2016/107454 WO2017097132A1 (zh) | 2015-12-09 | 2016-11-28 | 定点突变改造的酵母二肽基肽酶iii |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510908511.8A CN105368806B (zh) | 2015-12-09 | 2015-12-09 | 一种定点突变改造的酵母二肽基肽酶iii |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105368806A true CN105368806A (zh) | 2016-03-02 |
CN105368806B CN105368806B (zh) | 2016-08-24 |
Family
ID=55371438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510908511.8A Active CN105368806B (zh) | 2015-12-09 | 2015-12-09 | 一种定点突变改造的酵母二肽基肽酶iii |
Country Status (3)
Country | Link |
---|---|
US (1) | US20190246664A1 (zh) |
CN (1) | CN105368806B (zh) |
WO (1) | WO2017097132A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017097132A1 (zh) * | 2015-12-09 | 2017-06-15 | 暨南大学 | 定点突变改造的酵母二肽基肽酶iii |
CN110564634A (zh) * | 2018-06-06 | 2019-12-13 | 江苏师范大学 | 一株胞外分泌表达桦褐孔菌二肽酶的工程菌 |
CN111394339A (zh) * | 2020-03-18 | 2020-07-10 | 华东师范大学 | 一种基于酵母二肽基肽酶ⅲ的抗体模拟物及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4127157A4 (en) * | 2020-03-24 | 2024-04-24 | Encodia, Inc. | MODIFIED DIPEPTIDE CLIVASES, CORRESPONDING USES AND CORRESPONDING KITS |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309868B1 (en) * | 1997-07-05 | 2001-10-30 | Nestec S.A. | Cloning of the prolyl-dipeptidyl-peptidase from Aspergillus oryzae |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6485955B1 (en) * | 1997-10-06 | 2002-11-26 | The Trustees Of Tufts University | Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease |
CN101003574B (zh) * | 2006-02-21 | 2010-12-15 | 大连帝恩生物工程有限公司 | 长效降血糖肽的重组表达及其在糖尿病治疗药物中的应用 |
CN105368806B (zh) * | 2015-12-09 | 2016-08-24 | 暨南大学 | 一种定点突变改造的酵母二肽基肽酶iii |
-
2015
- 2015-12-09 CN CN201510908511.8A patent/CN105368806B/zh active Active
-
2016
- 2016-11-28 WO PCT/CN2016/107454 patent/WO2017097132A1/zh active Application Filing
- 2016-11-28 US US15/780,903 patent/US20190246664A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309868B1 (en) * | 1997-07-05 | 2001-10-30 | Nestec S.A. | Cloning of the prolyl-dipeptidyl-peptidase from Aspergillus oryzae |
Non-Patent Citations (2)
Title |
---|
JUNZO HIROSE ET AL.: "Junzo Hirose et al. Characterization of the Metal-Substituted Dipeptidyl Peptidase III (Rat Liver)", 《BIOCHEMISTRY》 * |
NICA ET AL: "Identification of the reactive cysteine residues in yeast dipeptidyl peptidase III", 《BIOCHIMIE》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017097132A1 (zh) * | 2015-12-09 | 2017-06-15 | 暨南大学 | 定点突变改造的酵母二肽基肽酶iii |
CN110564634A (zh) * | 2018-06-06 | 2019-12-13 | 江苏师范大学 | 一株胞外分泌表达桦褐孔菌二肽酶的工程菌 |
CN110564634B (zh) * | 2018-06-06 | 2021-04-27 | 江苏师范大学 | 一株胞外分泌表达桦褐孔菌二肽酶的工程菌 |
CN111394339A (zh) * | 2020-03-18 | 2020-07-10 | 华东师范大学 | 一种基于酵母二肽基肽酶ⅲ的抗体模拟物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105368806B (zh) | 2016-08-24 |
US20190246664A1 (en) | 2019-08-15 |
WO2017097132A1 (zh) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2147104T3 (en) | USING A ASPARAGINPROTEASE- (NSP24) SIGNAL SEQUENCE FOR heterologous protein EXPRESSION | |
CN105368806B (zh) | 一种定点突变改造的酵母二肽基肽酶iii | |
CN108085306B (zh) | 一种玉米赤霉烯酮降解酶突变体及其编码基因和应用 | |
JP3878207B2 (ja) | osmB プロモータで制御される発現プラスミド | |
CN107099521B (zh) | 一种耐酸性玉米赤霉烯酮解毒酶及其编码基因与应用 | |
CN111394333A (zh) | 一种赭曲霉毒素解毒酶及其编码基因、重组载体及应用 | |
Kim et al. | Comparative analysis of two types of methanol dehydrogenase from Methylophaga aminisulfidivorans MPT grown on methanol | |
TWI609081B (zh) | 內酯酶的用途及利用內酯酶降解 α-玉米赤黴烯醇的方法 | |
CN105400755B (zh) | 一种定点突变改造的人二肽基肽酶iii | |
CN102618517A (zh) | 不动杆菌的zen毒素降解酶及其编码基因与应用 | |
CN105400756B (zh) | 一种定点突变改造的大鼠二肽基肽酶iii | |
CN112824527B (zh) | 人工设计的赖氨酰内切酶及编码序列和发酵方法 | |
EP4032983A1 (en) | Ferulic acid decarboxylase mutant derived from saccharomyces, and method for producing unsaturated hydrocarbon compound using same | |
CN108034642B (zh) | 葡萄糖氧化酶CnGOD19及其改良酶、基因和应用 | |
CN117088946A (zh) | 一种环状细菌素as-48的全生物合成方法 | |
CN114317469B (zh) | 一种黄素单加氧酶突变体及其制备和应用 | |
KR100803095B1 (ko) | 바실러스 서브틸리스 ch2 유래의 키토산아제를 코딩하는유전자, 이 유전자를 포함하는 발현벡터, 이 발현벡터로형질전환된 형질전환체 및 이로부터 생산되는 단백질의정제방법 | |
WO2023054315A1 (ja) | コラーゲントリペプチド製造又は軟骨分解のための酵素剤 | |
CN111466511B (zh) | 含有去环氧基蛋白酶的组合物及脱毒方法 | |
WO2021174950A1 (zh) | 具有去环氧基催化活性的多肽及其编码核酸和用途 | |
CN107400665A (zh) | 一种定点突变的甘露聚糖酶及其应用 | |
CN109096383B (zh) | 一种鱼源抗菌肽parasin I突变体及其应用 | |
EP0759474B1 (en) | A regulatory factor involved in expression of nitrilase gene, and its gene | |
CN105063066A (zh) | 一种蜡样芽孢杆菌亚硝酸盐还原酶及基因和应用 | |
CN107058432B (zh) | 一种非甲醇诱导生产抗菌肽的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170918 Address after: 529339, No. 1, Huan Xin Road, Sha Hai Town, Guangdong, Kaiping Patentee after: Guangdong Fang can animal health care Co., Ltd. Address before: 510632 Whampoa West Road, Guangdong, Guangzhou, No. 601, No. Patentee before: Jinan University |